Reproductive Health News

Among people who gave birth between 2014 and 2018, those who identified as transgender experienced similar rates of severe parental morbidity and preterm birth as cisgender parents regardless of insurance type, researchers reported in JAMA.

Early IUD placement at 2 to 4 weeks postpartum was noninferior to placement at 6 to 8 weeks postpartum for expulsion, but not partial expulsion, according to a randomized noninferiority trial published in JAMA.

Women exposed to higher concentrations of per- and polyfluoroalkyl substances during pregnancy have children with higher BMI z scores and greater risks for overweight or obesity at age 2 to 5 years, according to study data.

More comprehensive health insurance coverage may be associated with greater postpartum visit attendance and fewer preventable hospital readmissions and ED visits, according to a systematic review published in JAMA Network Open.

BALTIMORE — In the wake of the Dobbs decision, a new energy surrounds self-managed abortions as a choice some people may make in the face of abortion restrictions, according to panelists at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — COVID-19 vaccination status did not significantly reduce the likelihood of becoming pregnant after intrauterine insemination, according to findings presented at the ACOG Annual Clinical & Scientific Meeting.

BALTIMORE — Maternal age in women with preeclampsia or gestational hypertension with severe features was associated with higher postpartum readmission risk, while intensive hypertension treatment at initial admission may limit risk.

Breastfeeding has lasting beneficial effects on cardiometabolic health, including lowering the risk for type 2 diabetes and cardiovascular disease, for mothers and obesity in their children, according to a life course epidemiologist.

BALTIMORE — In a new study, emotional distress was negatively associated with negative sleep, including decreased deep sleep and increased REM sleep during pregnancy.

BALTIMORE — New phase 3 data demonstrate efficacy of an investigational next-generation, hormone-free, low-dose copper IUD for prevention of pregnancy through 3 years of use.